-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4926 Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021

Program: Oral and Poster Abstracts
Session: 905. Outcomes Research—Lymphoid Malignancies: Poster III
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Study Population, Human
Monday, December 12, 2022, 6:00 PM-8:00 PM

Adrian Alegre, MD1*, Luis Juarez-Salcedo, MD2*, Víctor Jiménez-Yuste, MD, PhD3*, Julio Garcia-Suarez4*, José Luis Díez-Martín, MD, PhD5, Joaquín Martínez-López, MD, PhD6*, Beatriz Aguado, MD7*, José Ángel Hernández-Rivas8*, Lauren Benito9*, Pilar Martinez-Barranco10*, Javier López Jiménez, MD, PhD11*, Pedro Sanchez-Godoy, MD12*, Fj Peñalver, MD10*, Alberto Velasco, MD13*, Adriana Pascual14*, Celina Benavente Cuesta15*, María Pilar Llamas Sillero, MD, PhD16*, Juan Francisco DEL Campo17*, Elena Ruiz18*, Regina Herraez, MD19*, Javier Ortiz, MD20*, Carolina Miranda21* and Gregorio Garrido22*

1Hospital Universitario de La Princesa, Madrid, Spain, Madrid, Spain
2Hospital Universitario La Princesa, Madrid, Madrid, Spain
3Hospital Universitario La Paz, Autónoma University, Madrid, Spain
4Hospital Universitario Principe de Asturias, Alcala De Henares, ESP
5Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
6Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
7Hospital Universitario de La Princesa, Madrid, Spain
8Hematology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
9Hematology, Hospital de Getafe, Madrid, ESP
10Hematology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
11Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain
12Hematology Department, Hospital Universitario Severo Ochoa, Madrid, Spain
13Hematology, Hospital Universitario Rey Juan Carlos, Madrid, Spain
14Hospital Universitario Infanta Elena, Madrid, Spain
15Department of Haematology, Hospital Clínico San Carlos. Madrid, Spain, Madrid, ESP
16Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
17Hospital Universitario del Henares, Coslada, ESP
18Hospital del Tajo, Madrid, Spain
19Hospital Universitario Infanta Sofía, Madrid, Spain
20Hospital Universitario La Princesa, Madrid, Spain
21Hospital Universitarios Rey Juan Carlos, Madrid, Spain
22Oficina de registro de Tumores de Madrid (RTMAD), Madrid, Spain

Introduction: Epidemiological incidence studies of hematological neoplasms are essential to assess health outcomes. The region of Madrid has a tumor registry called RTMAD, which collects the incidence of neoplasms in all public centers in the community. We present the impact of the COVID-19 pandemic on the data collection of this registry, as well as the main hematological diseases incidence analysis between 2014-2021.

Aims: To assess the impact of the COVID19 pandemic on the collection of the incidence of hematological neoplasms in the RTMAD registry.

Patients and Methods: A retrospective analysis of the total number of cases registered between 2014 and 2021 on the platform of the Tumor Registry of the Community of Madrid (RTMAD) of the Regional Oncology Coordination Office was performed. The data corresponds to 27 public hospitals included in this registry with a total population of 6,5 million inhabitants. To evaluate the incidence, we used the coding and the statistical methodology that appears in the RTMAD reports.

Results: During the 2014-2021 period, a total of 22,617 cases of neoplasms were collected. Comparing the preexisting registered data, a 10% reduction in the total number of reported cases (3,278 fewer cases) was observed in 2020, with a slight recovery in 2021, although not to pre-pandemic levels. Of the total number of cases, hematological neoplasms represented 8.99%. The distribution of the main hematological diagnoses is shown in a specified way in Figure 1. The incidence data in crude rate (Figure 2) are somewhat lower than those estimated for the Spanish territory as a whole in the REDECAN Report of 2021 (Med Clin; 2022, Vol 158,6, 284-209) and those from international registries (ECIS, https://ecis.jrc.ec.europa.eu; SEER,https://seer.cancer.gov/statfacts/more.html).

Conclusions: The hematological neoplasms registry in the two years of the COVID-19 pandemic has been reduced by between 8-10% compared to 2019. This underreporting could be explained by high healthcare pressure with delay or undiagnosed patients, considering that the region of Madrid had a high incidence of SARS-CoV2 infections. A more detailed analysis of these causes and their comparison with other international records including impact on survival are ongoing.

Disclosures: Jiménez-Yuste: Roche, Novo Nordisk, Sanofi, Sobi, Takeda, Grifols, Bayer, Pfizer, Spark, BioMarin, Octapharma, CSL Behring: Consultancy; Roche, NovoNordisk, Sanofi, Sobi, Takeda, Grifols, Bayer, Pfizer, Octapharma, CSL Behring: Research Funding; Roche, NovoNordisk, Sanofi, Sobi, Takeda, Grifols, Bayer, Pfizer, Spark, Octapharma, CSL Behring: Honoraria. Hernández-Rivas: BMS/Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Beigene: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Rovi: Membership on an entity's Board of Directors or advisory committees; Takeda: Speakers Bureau; Lilly: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

*signifies non-member of ASH